Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$38.49 USD
-0.67 (-1.71%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $38.48 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
IONS 38.49 -0.67(-1.71%)
Will IONS be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for IONS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IONS
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag
AstraZeneca Stock Up Almost 14% in 6 Months: Time to Buy?
IONS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering
Why Is Zoetis (ZTS) Up 1.4% Since Last Earnings Report?
Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals
Other News for IONS
Spotlight On SMID-Caps: Morningstar's Undervalued Picks
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Ionis Pharmaceuticals (IONS) and Amicus (FOLD)
Wolfe’s tax loss selling stocks within communications, discretionary, staples, energy, financials, health care
Ionis Pharmaceuticals price target lowered by $5 at Guggenheim, here's why
Interest Rate Regimes And ARKG: Underperformance Explained